First and only treatment approved for both PAH and
inoperable or persistent/recurrent CTEPH after surgery†
*
Stimulating
*Soluble Guanylate Cyclase
What could Adempas
mean to your patients?
INDICATIONS
†
• Adempas (riociguat) tablets are indicated for the
treatment of adults with persistent/recurrent chronic
thromboembolic pulmonary hypertension (CTEPH),
(WHO Group 4) after surgical treatment, or inoperable
CTEPH, to improve exercise capacity and WHO
functional class.
• Adempas is indicated for the treatment of adults with
pulmonary arterial hypertension (PAH), (WHO Group 1),
to improve exercise capacity, WHO functional class and
to delay clinical worsening.‡
Efficacy was shown in patients on Adempas monotherapy
or in combination with endothelin receptor antagonists
or prostanoids. Studies establishing effectiveness included
predominantly patients with WHO functional class II–
III and etiologies of idiopathic or heritable PAH (61%) or
PAH associated with connective tissue diseases (25%).
‡
Time to clinical worsening was a combined endpoint
defined as death (all-cause mortality), heart/lung
transplantation, atrial septostomy, hospitalization due to
persistent worsening of pulmonary hypertension, start
of new PAH-specific treatment, persistent decrease in
6MWD [